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Pre-mRNA splicing is a crucial step in gene expression, and accurate recognition of splice sites is an essential part of this
process. Splice sites with weak matches to the consensus sequences are common, though it is not clear how such sites are
efficiently utilized. Using an in vitro splicing-complementation approach, we identified PUF60 as a factor that promotes
splicing of an intron with a weak 39 splice-site. PUF60 has homology to U2AF
65, a general splicing factor that facilitates 39
splice-site recognition at the early stages of spliceosome assembly. We demonstrate that PUF60 can functionally substitute for
U2AF
65 in vitro, but splicing is strongly stimulated by the presence of both proteins. Reduction of either PUF60 or U2AF
65 in
cells alters the splicing pattern of endogenous transcripts, consistent with the idea that regulation of PUF60 and U2AF
65 levels
can dictate alternative splicing patterns. Our results indicate that recognition of 39 splice sites involves different U2AF-like
molecules, and that modulation of these general splicing factors can have profound effects on splicing.
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INTRODUCTION
Accurate pre-mRNA splicing is essential for proper gene
expression. Introns must be spliced out of pre-mRNA and exons
ligated in order to make mature mRNA. Disease-causing
mutations that affect the splicing process are common, and testify
to the importance of splicing for normal cellular function. The
splicing process is made more complex by the fact that many pre-
mRNAs can be spliced in more than one way to give mature
transcripts coding for proteins with distinct functions. Such
alternative splicing greatly expands the coding capacity of the
human genome and contributes to the overall complexity of gene
expression [1]. Alternative splicing is often regulated in a tissue-
and developmentally-specific manner, and is also affected by
signaling pathways.
Intron removal is carried out by the spliceosome, a large
complex comprised of protein and RNA components. Among
these components are the U1, U2, U4, U5 and U6 small
ribonucleoprotein particles (snRNPs) which consist of a specific
small nuclear RNA (snRNA) and associated proteins. Assembly of
the spliceosome onto pre-mRNA is a dynamic process that
involves recognition of splice-site sequences at the ends of introns
(reviewed in [2]). For most introns, the conserved splice-site
sequences include a 59 splice-site element surrounding a GT
dinucleotide, and a 39 splice-site AG dinucleotide preceded by
a polypyrimidine tract and an upstream branchpoint sequence.
These splice-site elements are initially recognized by U1 snRNP,
which binds at the 59 splice site, and by SF1/mBBP, U2AF
65 and
U2AF
35, which bind cooperatively to the branchpoint sequence
[3,4], polypyrimidine tract [5,6] and 39 splice-site AG dinucleotide
[5,7,8,9], respectively.
A conserved family of splicing factors called SR proteins also
facilitates the earliest recognition of the 59 and 39 splice sites (for
review [2]). These first interactions between the spliceosome and
the pre-mRNA are important in identifying splice sites and
committing an intron to splicing. Once an intron has been initially
identified, U2 snRNP becomes stably associated with the pre-
mRNA. Recruitment of the U4/U6.U5 tri-snRNP to the
transcript initiates the formation of a mature spliceosome that is
poised to catalyze intron excision (for review, see [10]).
As a general rule, strong matches to the splice-site consensus
sequences are good predictors of efficient splicing. However, there
are many cases of introns with weak splice sites that are
constitutively spliced, and examples of alternative splicing in
which apparently weak splice sites are utlilzed more efficiently
than splice sites with stronger matches to the consensus sequence
[11,12]. Our current understanding of the determinants of exon
identity and intron splicing is limited. The well-defined consensus
sequences at the 59 and 39 splice sites do not contain sufficient
information to accurately identify bona fide splice sites [13],
suggesting that additional sequence features are involved in the
recruitment of the spliceosome to the correct location. Some of
these features include exonic and intronic enhancer and silencer
elements, which are recognized by distinct classes of RNA-binding
proteins [14].
Based on biochemical purification of the spliceosome, nearly
200 proteins are estimated to be involved in splicing (for review,
see [15]). However, only a fraction of these proteins currently have
established roles in splicing. Identification of factors that are
important for the recognition of weak splicing signals with poor
matches to the splicing consensus sequences is an important goal
towards understanding the mechanisms involved in splice-site
selection and splicing regulation and fidelity. Such factors may
play fundamental roles in tissue-specific or developmentally
regulated splicing events, which often result from the use of
apparently weak splice sites. In addition, studying the splicing of
introns with weak splice sites may facilitate the identification of
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PLoS ONE | www.plosone.org 1 June 2007 | Issue 6 | e538splicing factors that are important for splicing in vivo, but may be
dispensable for detection of basal splicing of introns with strong
consensus splice sites, which have traditionally been used in most
mechanistic studies of splicing in vitro.
We were interested in identifying splicing factors required for
the splicing of weak splice sites. We developed an in vitro splicing
complementation assay in which splicing of a substrate with
a weakened 39 splice site is restored upon addition of a fraction of
HeLa cell nuclear extract. We identified PUF60 as a protein that
stimulated splicing in this assay. PUF60 was previously implicated
in splicing [15,16], though direct evidence for its role in the
reaction was lacking. We now provide direct evidence that PUF60
is a splicing factor involved in 39 splice-site recognition. We find
that for some substrates, PUF60 can activate splicing in the
absence of the related splicing factor U2AF
65 and thus may
function in a similar capacity. We further demonstrate that PUF60
and U2AF
65 can function cooperatively in splicing, and that
modulating their levels in cells affects specific alternative splicing
events. Our results suggest the existence of a splicing regulatory
pathway controlled by a class of general splicing factors that is
involved in the recognition of the 39 splice-site region.
RESULTS
Identification of PUF60 as a Splicing Factor
Pre-mRNA splicing in vitro can occur accurately in HeLa cell
nuclear extract. The cytoplasmic S100 fraction obtained during
the preparation of nuclear extract is also competent for splicing of
many substrates when complemented with one or more SR
proteins [17,18]. We identified a pre-mRNA transcript that, as
a result of mutations in the pyrimidine tract, requires additional
nuclear factors to achieve high levels of splicing in S100 extract.
This transcript is derived from the human b-globin gene, with
modified sequences between the branchpoint sequence and the 39
splice site (Figure 1A; [19]). In this case, the parental substrate
(WT) is spliced efficiently in HeLa nuclear extract, as well as in
HeLa S100 extract complemented with SR proteins, such as
recombinant SC35 (Figure 1B). When four pyrimidine residues
near the branchpoint sequence were substituted with guanines
(PyD) (Figure 1A), there was little difference in the splicing of the
two substrates in nuclear extract (Figure 1B). However, splicing of
the weakened intron substrate (PyD) was severely compromised in
S100 extract complemented with SC35 (Figure 1B). Deficient PyD
splicing could be rescued by the addition of a 20-40% ammonium
sulfate fraction of nuclear extract (Figure 1B). The ammonium
sulfate fraction enhanced splicing of the WT substrate as well,
though not to the same degree as it stimulated PyD. We refer to
this activity that can rescue splicing of the PyD substrate as
RESCUE (Required for Efficient Splicing Complementation in
Unproductive Extract).
The splicing factor U2AF
65 was a possible candidate for
RESCUE activity because it recognizes the pyrimidine tract
during the splicing reaction [5]. However, western analysis showed
a substantial amount of U2AF
65 in S100 extract (Figure 1E). We
also found that recombinant U2AF
65/35 that complements splicing
in a U2AF depletion assay (Figure S1A) was not able to comple-
ment splicing in our S100 complementation assay (Figure S1B)
indicating that U2AF
65/35 are not responsible for RESCUE
activity.
We purified RESCUE activity by sequential biochemical
fractionation (Figure 1C). Following each step of purification,
fractions were assayed for their activity in splicing of PyD pre-
mRNA in S100 extract supplemented with SC35. Active fractions
were pooled and purified further. As a first step, RESCUE activity
in the 20–40% ammonium-sulfate precipitate was subjected to
density-gradient centrifugation in cesium chloride (CsCl). The
active fractions from the CsCl gradient were loaded on a Poros
HE1 heparin column and RESCUE activity eluted at high salt
(data not shown). We next disrupted protein-protein interactions
in the active fractions by urea denaturation, and separated the
pooled fractions on a Poros HQ column in the presence of urea
(Figure 1C). Proteins associated with RESCUE activity bound to
the column and were eluted at low salt concentrations (Figure S2).
The most active fraction (Figure 1C, fraction 18) comprised
a limited number of polypeptides, as analyzed by SDS-PAGE
(Figure 1D). To identify the proteins, the entire fraction was
digested with trypsin and the resulting peptides were identified by
liquid chromatography tandem mass spectrometry (LC/MS/MS).
Peptides from two proteins were detected: PUF60 (also known as
FIR, RoBP1 and siah-bp1) and DDB1. DDB1 is a UV-damaged-
DNA binding protein involved in nucleotide excision repair; it is
structurally related to the U2-snRNP-associated protein SF3b130,
but otherwise has no obvious link to splicing [20].
PUF60 is related to U2AF
65, which has an important role in 39
splice site recognition, and is thus a good candidate for RESCUE
activity. We confirmed the presence of PUF60 in the HQ fraction
with RESCUE activity by western blotting (Figure 1D). PUF60
migrates as a monomer and as an SDS-resistant dimer on SDS-
PAGE; the latter form was detected in addition to the monomer in
the heparin fraction (Figure 1D).
To confirm that PUF60 is the primary factor responsible for
RESCUE activity, we generated recombinant PUF60 in E. coli
(Figure 1E). The addition of rPUF60 to S100 extract with SC35
stimulated PyD splicing (Figure 1F) demonstrating that PUF60
activates PyD splicing in the RESCUE splicing assay. Western blot
analysis revealed that PUF60 is present predominantly in nuclear
extract, with substantially lower levels in S100 extract (Figure 1E),
which explains why the addition of PUF60 to the extract
stimulates splicing in our complementation assay. In contrast,
the level of U2AF
65 in S100 extract is comparable to the level in
nuclear extract (Figure 1E).
PUF60 has been previously identified as a component of
purified spliceosomes (reviewed in [15] and is associated with the
17S U2 snRNP [21]. PUF60 was originally found in a highly
purified fraction of nuclear extract that contained both PUF60 and
the splicing factor SRp54. This fraction, but not purified
recombinant PUF60 alone, complemented splicing when com-
bined with U2AF
65/35 in extract depleted of poly(U)-binding
proteins [16]. Because this previous report did not demonstrate
that recombinant PUF60 could complement splicing, which is the
definitive criterion for demonstrating a functional role for
a protein, it has been unclear whether PUF60, SRp54 or
additional unidentified factors were responsible for the splicing
activity of the purified fraction. Thus, our finding that PUF60 can
complement splicing in S100 extracts is the first formal
demonstration that human PUF60 is a functional splicing factor.
PUF60 Associates with Splicing Factors Involved in
Early Spliceosome Assembly
To better understand the role of PUF60 in splicing, we identified
PUF60-interacting proteins using a HeLa cell line with stable-
integration of PUF60 cDNA fused to tandem N-terminal FLAG
and V5 epitope tags (Figure 2A). Nuclear extract was prepared
from these cells and PUF60 was immunoprecipitated with anti-
FLAG antibody linked to agarose beads (Figure 2B). PUF60 and
co-immunoprecipitated proteins were eluted from the beads with
excess FLAG peptide, and were then separated by SDS-PAGE
PUF60 Regulates Splicing
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mass spectrometry. To thoroughly characterize proteins that
specifically associate with PUF60, we performed a parallel
experiment in which immunoprecipitates from F-V5-PUF60
HeLa nuclear extract or from control HeLa nuclear extract were
digested with trypsin directly on the beads (Figure 2B). Released
Figure 1. Identification of PUF60 as a Splicing Activator (A) Schematic of the wild-type (WT) and mutant (PyD) splicing substrates [19]. Boxes
represent exons and lines are introns. Mutations are in lower case and the corresponding nucleotides in the wild-type substrate are underlined. Bold
A indicates the branchpoint. (B) In vitro splicing assays were carried out in HeLa nuclear extract (NE) or S100 extract complemented with recombinant
SC35, with or without a 20–40% ammonium sulfate (AS) fraction from HeLa NE. Quantitation is shown as the percent of the total RNA that is spliced.
(C) Scheme for purification of the complementing activity and quantitation of RESCUE activity in HQ column fractions spanning the peak of activity.
Splicing activity was normalized to the input material (H*). (see also Figure S2). H* refers to the HQ column input that was denatured with urea and
renatured. (D)(top) Silver-stained SDS-PAGE of HQ peak fractions. (bottom) Western blot analysis of heparin (H) and HQ fractions 14-21. PUF* refers to
an SDS-resistant dimer of the protein [16]. (E) Western blot analysis of S100 (lanes 1,4; 4 ml), NE (lanes 2,5; 4 ml), and recombinant PUF60 from E. coli
(lane 3) using a PUF60 (lane 1–3) or U2AF
65-specific (lane 4,5) antibody. (F) In vitro splicing assay using the PyD substrate in reactions containing S100
extract with SC35 alone (lane 2; 3 ml) and complemented with PUF60 purified from E. coli (lanes 3–4; 1 and 2 ml).
doi:10.1371/journal.pone.0000538.g001
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etry. Using these two methods, proteins specifically associated with
PUF60 were identified. The results from both experiments were
compiled, and only proteins identified in both experiments and
absent from control samples were classified as PUF60-associated
proteins with a high degree of confidence (Table 1).
Strikingly, most of the proteins that co-immunoprecipitated
with PUF60 are known splicing factors. Nine SR proteins, as well
as U1 and U2 snRNP-associated proteins make up the majority of
the proteins associated with PUF60 (Table 1). These splicing
factors function at early steps of the splicing reaction, during the
initial recognition and specification of splicing signals. Consistent
with the mass-spectrometry data, western analysis confirmed the
presence of several proteins identified in the PUF60 immunopre-
cipitates (Figure 2C).
Functional Redundancy and Synergy between
PUF60 and U2AF
65/35
PUF60 has sequence and structural homology to U2AF
65 [22]
suggesting that the two proteins may have related functions in
splicing. To investigate this possibility, we compared the ability of
PUF60 and U2AF
65 to complement splicing in extract depleted of
both factors. We performed poly(U)-Sepharose chromatography of
nuclear extract, which effectively generates extract depleted of
these proteins (Figure S3A; [16,23]. The flow-through (NED)
removes more than 98% of poly(U)-binding factors, such as
PUF60, U2AF
65, and U2AF
35 (Figure S3B, S3C and S3D) and
does not support splicing of PyD or other substrates in vitro
(Figure 3). This depletion method does not alter the levels of other
nuclear splicing factors tested, such as SF2/ASF (Figure S3B).
To test the ability of U2AF and PUF60 to complement splicing
in the depleted extract, we expressed His-tagged PUF60 or His-
tagged U2AF
35 in HEK-293E cells and purified the proteins by
nickel-agarose chromatography (Figure S3C and S3D). His-tagged
U2AF
35 co-purifies with U2AF
65 (Figure S3D), reflecting the
strong interaction of these two proteins [16]. Purified PUF60 was
unable to complement PyD splicing in the depleted extract
(Figure 3A) and U2AF
65/35 provided only very marginal
complementation. However, when added in combination,
PUF60 and U2AF
65/35 stimulated PyD splicing. Our results using
this depletion assay confirm our previous results from the S100-
extract complementation assay (Figure 1F) that PUF60 has a role
in PyD splicing, and suggest a mechanism for its activity that
involves U2AF
65/35.
We next tested whether the requirement for PUF60 in splicing
and the cooperative action of PUF60 and U2AF
65/35 are specific
for PyD, or whether this activity is more general. We tested the
natural b-globin intron 1, from which PyD was originally derived,
and found that the purified U2AF complex activated b-globin
splicing to a higher degree than PyD (Figure 3B). Similar to our
results with PyD, the addition of PUF60 and U2AF
65/35 together
had a strong cooperative effect on splicing (Figure 3B). This result
supports our finding that the PyD substrate is more dependent on
PUF60 for splicing (Figure 1). U2AF
65 is generally considered
essential for pre-mRNA splicing [24,25]. Surprisingly, in the
absence of the U2AF heterodimer, PUF60 complemented splicing
to some degree (Figure 3B). Overall, our results indicate the
PUF60 and U2AF
65/35 function synergistically in splicing, but are
also able to functionally replace each other in the splicing of some,
but not all substrates.
To further investigate this U2AF-independent splicing phenom-
enon, as well as the synergistic activity of PUF60 and U2AF
65/35 in
splicing, we tested additional substrates, including C12 [26], d-
crystallin [27] and ftz [28]. We found that splicing of these
substrates could be complemented by PUF60 in the depleted
extract (Figures 3C and 3D and S4). The complementing activities
of PUF60 and U2AF
65/35 were comparable for the C12 substrate
(Figure 3C). In contrast, U2AF
65/35 was more active than PUF60
in complementing d-crystallin (Figure 3D) and ftz splicing (Figure
S4). The amount of U2AF
65/35 added to the reaction was
considerably lower than that of PUF60, because the specific
activity of recombinant PUF60 appears to be lower than that of
Figure 2. Identification of PUF60-associated Proteins. (A) Western blot analysis of nuclear extract (NE) prepared from control untransfected HeLa
cells (C, lane 1) or cells expressing the FLAG-V5-tagged PUF60 protein (F-V5-PUF, lane 2). Blots were probed with antibodies specific for PUF60 and U2
snRNP B’’. (B) Silver-stained 4–20% gradient SDS-PAGE of FLAG-PUF60 (PUF, lanes 1, 3) or control (C, lanes 2,4) immunoprecipitates, either bound to
the a-FLAG beads (lanes 1,2) or eluted from the beads with FLAG peptide (lanes 3,4). The heavy chain (*) and light chain (**) from the FLAG antibody
are indicated. (C) Western blot analysis of FLAG-PUF60 immunoprecipitates eluted with FLAG peptide.
doi:10.1371/journal.pone.0000538.g002
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65/35. This difference may reflect the intrinsic activities of
the proteins in the splicing reaction, or it may be due to differences
in the specific activities of the recombinant protein preparations.
For example, the PUF60 recombinant protein may lack a co-
factor—analogous to the U2AF
65/35 relationship—that could be
critical for maximum activity. In any case, our results indicate that
U2AF
65/35 is not strictly required for splicing in vitro when PUF60
is present.
A striking synergistic effect of PUF60 and U2AF
65/35 on splicing
was observed for all splicing substrates we tested. The addition of
increasing amounts of U2AF
65/35 to extract containing a fixed
amount of PUF60, or vice-versa (Figures 3C and 3D and S4),
resulted in a.5-fold stronger activation of splicing relative to
reactions in which comparable amounts of PUF60 or U2AF
65/35
were added to the extract in the absence of the other. The
expected level of splicing if the effect of these proteins on splicing is
additive was quantitated (Figures 3E and S4B, Sum) and was
substantially lower than the observed splicing when PUF60 and
U2AF
65/35 were present together in the extract (Figures 3E and
S4B). These results demonstrate the cooperative activity of PUF60
and U2AF
65/35 in splicing, and may also suggest differences in
substrate-specific requirements for these proteins.
Cooperative Binding of PUF60 and U2AF
65/35 to RNA
To explore the nature of the cooperative activity of PUF60 and
U2AF
65/35, we tested whether one protein influences the binding of
the other to a 39 splice site. We performed gel-shift experiments with
U2AF
65/35 heterodimer purified from baculovirus-infected SF9 cells
and recombinant PUF60 purified from human HEK-293E cells
(Figure S5). A 34-nt RNA substrate derived from the 39 end of
adenovirus major late pre-mRNA (Figure 4A) was used as a binding
substrate. This RNA has been extensively characterized for binding
by U2AF
65/35 and SF1/mBBP [3] and is therefore useful for
assessing the general contribution of PUF60 to binding in the 39
splice-site region. PUF60 and U2AF
65/35 were incubated with the
substrateand complexes were separated by nativegelelectrophoresis
and detected by autoradiography and phosphorimage analysis. The
proteins in the shifted complexes were identified by transferring the
gels to a membrane, followed by western blot analysis using PUF60
and U2AF
65 antibodies [29](Figure S6).
When added alone, PUF60 and the U2AF heterodimer each
bound the RNA substrate (Figure 4A). When PUF60 and U2AF
65/
35 were incubated together with the RNA, PUF60 binding was
enhanced as much as four-fold compared to binding in the
absence of U2AF
65/35 (Figure 4A, cf. lanes 3–5 with lanes 7–9 and
lane 3 with lanes 14–17). Interestingly, increasing amounts of
PUF60 binding to the RNA appeared to displace the U2AF
complex, as evidenced by the decrease in the U2AF:RNA
complex. Thus, U2AF
65/35 strongly facilitates PUF60 binding
and in so doing may destabilize its own binding. Alternatively, the
presence of PUF60 may alter the binding of U2AF
65 and result in
a less stable interaction with the RNA that does not withstand the
separation on the polyacrylamide gel. In any case, the cooperative
binding of PUF60 and U2AF
65/35 suggests that the activities of
these proteins in splicing may arise from collaboration during their
initial binding to the RNA.
In order to help define the interaction between the 39 splice-site
region and PUF60 and the U2AF
65/35 heterodimer and whether
these interactions change when the proteins are incubated
together, we performed footprinting experiments with the AdML
RNA substrate and purified proteins (Figure 5). Previous
footprinting analysis of this substrate with purified U2AF
65
revealed that the protein protects the pyrimidine tract and also
the branchpoint sequence to some degree [3]. To test whether
both PUF60 and U2AF
65/35 protect the pyrimidine tract, we
digested the RNA with RNase 1, which cleaves 39 of all four bases.
RNase1 did not cleave efficiently near the 59 end of the RNA, even
in the absence of protein. Nonetheless, we found that the U2AF
65/
35 heterodimer and PUF60 both protected the pyrimidine tract
Table 1. Proteins associated with PUF60
......................................................................
Accession # Protein Cal. Mass Peptides* log (e)*
SR proteins
SW:Q05519 SRp54 53542 25 2221
SW:QWXA9 SRrp86 71649 19 2165
SW:Q07955 SF2/ASF 27745 10 259
SW:Q13247 SRp55 39587 6 231
SW:Q13243 SRp40 31264 4 230
SW:Q16629 9G8 15763 5 226
SW:Q01130 SC35 25476 3 225
SW:Q13595 TRA-2 alpha 32689 2 217
SW:Q15815 TRA2-beta 33666 2 29
U1-associated
SW:P08621 U1 70K 51557 4 221
SW:P09012 U1A 31279 1 25
U2-associated
SW:O75533 SF3b155 145830 32 2239
SW:Q13435 SF3B145 97585 14 295
SW:Q15393 SF3B130 135577 5 239
SW:Q15459 SF3A120 88886 7 237
SW:Q15427 SF3b50 44386 4 237
SW:Q9Y3B4 SF3B14 14585 4 229
SW:Q12874 SF3A60 58849 2 217
SW:Q15393 SF3b130 135576 1 26
SW:P09661 U2 A’ 28415 1 21.4
Other splicing factors
SW:Q9UQ35 SRM300 299614 23 2171
SW:Q7L014 DDx46/prp5 117575 19 2122
SW:Q14498 HCC1 40541 7 251
SW:095218 ZN265 36318 5 227
SW:Q15287 RNPS1 34208 3 223
SW:P26368 U2AF65 53501 2 210
SW:Q9UMS4 Prp19 55180 2 23
RNA-related
SW:Q9Y383 LUC7L2 47506 8 253
SW:P38919 eIF4AIII/DDx48 46871 6 238
SW:Q9NQ29 LUC7L 38405 4 221
SW:O95232 CROP(LUC7a) 51466 3 213
SW:P35637 FUS 53426 2 210
SW:P05455 La 46837 2 26
SW:Q9Y580 RBM7 30503 1 27
SW:P10155 Ro 60KDa 60670 1 24
SW:Q14103 hnRNP D 38434 1 22
Others
NP_653205 NHN1 106378 7 245
*Results from experiment in which proteins are directly digested and sequenced
from beads.
doi:10.1371/journal.pone.0000538.t001
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PLoS ONE | www.plosone.org 5 June 2007 | Issue 6 | e538Figure 3. Cooperative Activity of PUF60 and U2AF
65/35 in Splicing. (A) Complementation of PyD splicing in vitro in nuclear extract depleted of
PUF60 and U2AF subunits using poly(U)-Sepharose. PyD pre-mRNA spliced in mock-depleted nuclear extract (NE, lane 1), extract depleted of U2AF
subunits and PUF60 (DNE, lane 2), depleted extract complemented with U2AF
65/35 purified from HEK-293E cells alone (lanes 3–6: 17, 33, 67, and
133 nM final concentration of U2AF
65, respectively) or with 67 nM of U2AF
65 plus recombinant PUF60 (lanes 7,8: 1.2 and 2.4 mM PUF60) or with
PUF60 alone (lanes 9,10: 1.2 and 2.4 mM). (B) Splicing of b-globin intron 1 in nuclear extract (NE, lanes 1, 8), or in poly(U)-depleted extract alone (DNE,
lanes 2,9). Depleted extract was complemented with purified U2AF
65/35 (lanes 3–5: 17, 33, and 133 nM final concentration of U2AF
65), with 670 nM of
U2AF
65 plus recombinant PUF60 (lanes 6,7: 1.2 and 2.4 mM,) or with PUF60 alone (lanes 10,11: 1.2 and 2.4 mM). (C) C12 and (D) d-crystallin pre-mRNA
spliced in nuclear extract (NE, lanes 1), depleted extract (DNE, lanes 2) or depleted extract with addition of recombinant PUF60 (lanes 3–5: 1.2, 2.4, and
4.8 mM final concentration; lanes 6–8: 1.2 mM; lanes 12–14, 0.6, 1.2, and 2.4 mM) or purified U2AF
65/35 (lanes 6–8: 33, 67, and 133 nM of U2AF
65; lanes
9–11: 67, 133, and 200 nM ; lanes 12–14: 670 nM). (E) Quantitation of C12 (left) and d-crystallin (right) splicing. Splicing was calculated at three
concentrations of protein (see C and D). PUF60 corresponds to quantitation of lanes 3–5; PUF60+U2AF
65 refers to lanes 6–8; U2AF refers to lanes 9–
11; and U2AF+PUF60 corresponds to lanes 12–14. The level of splicing expected if the PUF60 and U2AF activity is additive was calculated as the sum
of lanes 3+9, 4+10, and 5+11, respectively (Sum).
doi:10.1371/journal.pone.0000538.g003
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the protection pattern nor in the level of protection when the two
proteins were added in combination (lane 4). However, in order to
see efficient protection using this enzyme, a level of PUF60 and
U2AF
65/35 was required that was out of the range for cooperative
interactions, as judged by the gel-shift experiments. Thus, we were
not able to assess the cooperative protection of the RNA by PUF60
and U2AF
65/35 using RNase 1.
We also performed footprinting analysis with RNase T1, which
cleaves 39 of guanosines. We observed partial protection of the
guanosine at the 39 splice-site AG dinucleotide by PUF60 and
U2AF
65/35 when incubated individually, as evidenced by the
decrease in cleavage product 2 (Figure 5C and 5D). When PUF60
and U2AF
65/35 were added together to the reaction, the protection
pattern of the RNA was altered. An increase in protection of the
AG dinucleotide (product 2) as well as the guanosine in the
pyrimidine tract (product 3) suggests that the binding of the
proteins changes when both are present. These results suggest that
the cooperative binding seen in the gel shift assay may reflect
interactions at the pyrimidine tract that in turn stabilize binding to
the AG at the 39 splice site.
We also reproducibly observed U2AF
65/35 protection of the
branchpoint sequence region in the absence of PUF60 (Figure 5C,
lane 4, products 4,5,6), as previously reported [3]. PUF60 had the
opposite effect on accessibility in this region, causing enhanced
cleavage in this region (Figure 5C and 5D, product 4, 5, 6). These
effects on the branchpoint sequence may reflect non-specific binding
of the proteins. Interestingly, these effects were not observed when
the proteins were added together, suggesting that the presence of
both proteins increases or stabilizes specific binding.
Modulation of Alternative Splicing by PUF60 and
U2AF
65
We have shown that PUF60 and U2AF
65/35 function coopera-
tively during splicing in vitro, and that the absence of either protein
does not eliminate splicing but severely compromises its efficiency.
From these results, we reasoned that splicing activity and
alternative splicing might be regulated in vivo by variations in the
level of these two proteins. We found that the levels of PUF60 and
U2AF
65 do indeed vary between different cell-types. In particular,
the levels of PUF60 and U2AF
65 in HeLa cells are 3-5 fold higher
Figure 4. Cooperative Binding of U2AF
65/35 and PUF60 to the 39 splice site. (A) Electrophoretic mobility shift assay using a radiolabeled 34-nt RNA
derived from adenovirus major late (AdML) pre-mRNA, and recombinant PUF60 and U2AF
65/35. Complexes are indicated on the left. (B) Quantitation
of PUF60 binding to AdML RNA represented as the fraction of total labeled RNA bound by the protein. (C) U2AF
65 binding represented as the fraction
of total labeled RNA bound by the protein.
doi:10.1371/journal.pone.0000538.g004
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65/35 binding (A) RNase 1 digestion. Labeled RNA was incubated with purified PUF60, U2AF
65/35,
or both PUF60 and the U2AF heterodimer, digested with RNase and separated by denaturing PAGE. The concentration of PUF60 was 0.72 mM (lane 2),
or 0.36 mM (lane 4) and that of U2AF
65 was 1.9 mM (lane 3), or 0.96 mM (lane 4). (B) Graphical representation of footprint data in (A). Relative
protection is normalized to digestion in the absence of protein (A, lanes 1, 6). The RNA sequence below the plot indicates the position of cleavage
(arrowhead). The pyrimidine tract is underlined. (C) RNase T1 digestion. The concentration of PUF60 was 0.36 mM (lanes 7, 9) and that of U2AF
65 was
0.48 mM (lanes 8,9). The bands corresponding to the pyrimidine (Py) tract and branchpoint adenosine (A), and full-length RNA (FL) are indicated (see
also Berglund et al., 1998). RNase T1 cleavage sites are numbered. A lower exposure of the top of the RNase T1 gel allows visualization of cleavage
site 2. (D) Graphical representation of footprinting data in (C). Relative protection is normalized to digestion in the absence of protein (C, lanes 1, 6).
The RNA sequence below the plot indicates the position of cleavage (arrowhead). The pyrimidine tract is underlined.
doi:10.1371/journal.pone.0000538.g005
PUF60 Regulates Splicing
PLoS ONE | www.plosone.org 8 June 2007 | Issue 6 | e538than in the neuronal-like WERI-RB-1 cells (Figure S7). These
results indicate that the levels of the proteins are not constant and
may be controlled in a tissue-specific manner, which may
contribute to differences in alternative splicing between different
cells.
We investigated whether alternative splicing can indeed be
modulated by changing U2AF
65 and PUF60 levels in cells. We
used an RNAi approach to deplete PUF60 levels in cells. We first
created a HeLa cell line (PUFrm) with stable integration of
a PUF60 cDNA with silent mutations in the target region for an
Figure 6. Changes in PUF60 and U2AF
65/35 levels regulate alternative splicing in cells. (A) Western blot analysis of HeLa cells with stable expression
of empty vector (HeLa) or PUF60 cDNA with silent mutations that protect transcripts from siRNA-mediated knockdown (HeLa PUFrm). Cells were
treated with PUF60 siRNA (+) or mock-treated (2). Blots were probed with antibodies specific for PUF60, hnRNP A1, and U2 B’’. (B) Western blot
analysis of HeLa cells treated with siRNA specific for PUF60 (lane 2), a U2AF
65-specific siRNA (lanes 3 and 4) or mock-treated (lane 1). Antibodies
against U2AF
65, PUF60, or a-tubulin were used. (C) APP and (D) BIN1 alternative splicing analyzed by RT-PCR with [a-
32P]dCTP of endogenous
transcripts from stable cell lines mock-treated (lanes 1,3) or treated with PUF60 siRNA (lanes 2,4)(from (A)). (E) APP and (F) BIN1 alternative splicing
analyzed by RT-PCR with [a-
32P]-dCTP of endogenous transcripts from HeLa cells mock-treated (2) or treated with PUF60 (P), U2AF
65 (U) siRNAs, or
both (P+U). RT-PCR analysis of APP and BIN1 from untreated Weri-Rb1 (W) cells demonstrates neural splicing patterns.
doi:10.1371/journal.pone.0000538.g006
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alone. These cell lines were treated with the PUF60 siRNA. As
expected, PUF60 levels were reduced in the vector-control cell line
(Figure 6A). Because PUF60rm is not targeted by the siRNA, only
a slight reduction of PUF60, due to the reduction of endogenous
PUF60, was seen in the PUFrm cell line (Figure 6A).
PUF60 was previously identified in a yeast three-hybrid assay as
a factor that interacts with an intronic splicing enhancer located 36
nucleotides upstream of the 39 splice-site region of the amyloid
precursor protein (APP) transcript; this enhancer promotes
inclusion of the alternatively spliced exon 8 of APP transcript
[30]. APP alternative splicing is also regulated in a tissue-specific
manner: neuronal tissues favor exon 7 and 8 skipping (isoform 69).
whereas non-neuronal tissues exhibit nearly complete inclusion of
exon 7 and some exon 8 skipping (isoforms 6789 and
679)(reviewed in [31]. To determine whether PUF60 can
modulate APP alternative splicing, we performed RT-PCR to
analyze alternative splicing of endogenous APP transcripts in the
cells depleted of PUF60. We observed a decrease in transcripts
that include exon 8, and an increase in transcripts that skip exons 7
and 8, relative to APP transcripts from the control cells (Figure 6C).
No change in alternative splicing was observed in the knockdown
of PUF60 in the PUFrm cells (Figure 6C), indicating that the
change in APP alternative splicing was a direct and specific result
of PUF60 depletion. These results are consistent with the
aforementioned report that PUF60 interacts with a splicing
enhancer that is important for exon 8 splicing [19]. Skipping of
APP exons 7 and 8 is also the predominant isoform in WERI cells
(Figure 6E), which have lower levels of PUF60 than HeLa cells
(Figure S7). These findings may indicate a correlation between
skipping of these exons and PUF60 levels in brain.
We next tested for changes in additional alternative splicing
events following depletion of PUF60 from cells. Alternative
splicing of the tumor suppressor BIN1 is similar to that of APP
in that there are multiple alternatively spliced exons and a distinct
splicing pattern is observed in neuronally-derived samples [32].
Changes in the level of BIN1 isoforms have been linked to tumor
progression, which can be induced by modulation of the
expression levels of splicing factors [32,33]. We found that
PUF60 knockdown resulted in a reduction of BIN1 isoforms that
include exon 12A (Figure 6D). This splicing pattern is similar to
that observed in WERI cells (Figure 6F). Thus, knockdown of
PUF60 in HeLa cells results in a shift toward a neuronal-type
splicing pattern, similar to the shift in splicing observed in APP
transcripts following PUF60 depletion.
If different introns have different requirements for PUF60 and
U2AF
65, then depleting U2AF
65 in cells might be expected to have
different effects on alternative splicing than PUF60 depletion. To
test this idea, a U2AF
65-specific siRNA was used to deplete the
protein from HeLa S3 cells (Figure 6B). Consistent with above
results, PUF60 depletion caused an increase in exon 7 and exon 8
skipping (Figure 6E). In contrast, U2AF
65 depletion increased
exon 8 skipping, as evidenced by an increase in isoform 679
(Figure 6E). U2AF
65 knockdown also altered BIN1 splicing: unlike
PUF60 depletion, which favored exon 12A skipping (Figure 6F),
U2AF
65 depletion promoted exon 12A inclusion (Figure 6F).
These results suggest that the splicing of different introns is
differentially affected by changes in the levels of U2AF
65 and
PUF60. Knock-down of PUF60 and U2AF
65 together resulted in
a change in APP and BIN1 splicing similar to the pattern seen with
U2AF
65 knockdown alone (Figure 6E and 6F), suggesting that the
U2AF
65 effect may be dominant over the PUF60 effect on splicing.
We conclude from these results that modulation of the activity or
levels of PUF60 and U2AF
65 may contibute to the regulation of
alternative splicing.
We tested the effect of PUF60 and U2AF
65 depletion on the
splicing of several additional alternatively spliced exons, and
observed a spectrum of different responses. A single nucleotide
polymorphism in the pyrimidine tract of UBQLN1 intron 7 is
associated with partial skipping of exon 8 and has recently been
linked to an increased risk of Alzheimer’s disease [34]. We found
that exon 8 splicing was insensitive to changes in PUF60 levels in
HeLa cells (Figure 7A). However, depletion of U2AF
65 led to
a striking increase in exon 8 skipping. We also tested splicing of
SMN2 exon 7, which is a well-studied splicing event that is
influenced by a number of splicing factors (reviewed in [35]). We
found that knockdown of either PUF60 or U2AF
65 led to
a decrease in exon 7 skipping (Figure 7B). Finally, we tested
splicing of MAPT exon 10. Human mutations that alter MAPT
exon 10 splicing are linked to frontotemporal dementia with
Parkinsonism linked to Chromosome 17 (FTDP-17), and many
splicing factors have been documented to be involved in the
regulation of this splicing event (reviewed in [36]). We found that
alternative splicing of exon 10 was not significantly affected by
Figure 7. Complex modulation of alternative splicing by PUF60 and U2AF
65. (A) UBQLN1 exon 8 splicing, (B) SMN2 exon 7 splicing, and (C) MAPT
exon 10 splicing analyzed by RT-PCR in the presence of [a-
32P]-dCTP of endogenous transcripts from untreated (2) HeLa cells, HeLa cells treated with
a PUF60-specific siRNA (P), a U2AF
65 siRNA (U), or both siRNAs (P+U). Transcripts including the alternative spliced exon (+) or skipping the exon (D) are
labeled.
doi:10.1371/journal.pone.0000538.g007
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65 in HeLa cells (Figure 7).
Together, our results indicate that changes in the levels of PUF60
and U2AF
65 in cells do not alter splicing of all alternative exons.
Instead, changes in the quantity of these proteins appear to
selectively modulate alternative splicing of a subset of exons.
DISCUSSION
Introns with splice-site sequences with poor matches to the
consensus motifs are common in pre-mRNAs. Despite having
weak splicing signals, such introns can be excised efficiently in vivo.
The mechanisms responsible for the recognition and selection of
authentic splice sites, rather than cryptic sites or alternative
splicing pathways, are not clear. In particular, the highly specific
recognition of 39 splice sites is puzzling. The consensus sequence of
the 39 splice site is relatively simple, apparently requiring little
more than an AG dinucleotide preceded by a region moderately
enriched in pyrimidines and a degenerate branchpoint sequence.
Clearly, much more is involved in defining a 39 splice site, as this
combination of sequence elements is plentiful in genomic
sequences and yet 39 splice-site selection is highly specific and
subject to inactivation by single point mutations. It is apparent that
our current understanding of the 39 splice site is limited, and has
likely overlooked components that may be critical for the efficient
and specific recognition of sites that have poor matches to the
degenerate 39 splice-site consensus.
To gain insight into the mechanism of 39 splice-site recognition,
we investigated the factor requirements for splicing of an intron with
aw e a k3 9 splice site/pyrimidine tract, and identified PUF60 as
a critical protein for splicing (Figure 1). We showed that PUF60
stimulates splicing, and is in a complex with splicing factors involved
intheearlystepsofspliceosomeassembly(Figure2).Mechanistically,
PUF60 collaborated in a cooperative manner with U2AF
65/35 in
both RNA binding (Figures 4 and 5) and splicing activation
(Figure 3). Surprisingly, however, neither protein was essential for
splicing, provided that the other one was present indicating some
level of functional redundancy between these structurally related
proteins.Inaddition,modulationofthelevelsofU2AF
65 and PUF60
in cells changed alternative splicing patterns (Figures 6 and 7),
demonstrating that PUF60 and U2AF
65 can modulate the efficiency
of 39 splice-site selection in a splice-site-dependent manner, and
thereby regulate alternative splicing.
PUF60: a Multi-tasking Protein
PUF60 has long been considered a putative splicing factor due to
its presence in a number of purified spliceosomes (reviewed in
[15]), its similarity to U2AF
65 [22], as well as its presence in
a partially purified fraction of nuclear extract with splicing activity
in vitro [16]. In the latter study, PUF60 was shown to bind to
poly(U) RNA and was the predominant protein along with SRp54
in a partially purified fraction of nuclear extract that complemen-
ted splicing of extract depleted of poly(U) binding factors.
However, none of the functional assays done at that time used
recombinant PUF60. Thus, despite the suggestive evidence that
PUF60 was a splicing factor, rigorous proof of its function in
splicing was previously lacking. To demonstrate the activity of
PUF60 in splicing, we have used an S100 extract complementa-
tion assay, as well as the previous assay involving complementation
of poly(U)-depleted extracts. For the latter assay, we used different
substrates than Page-McCaw et al. [16], as well as recombinant
PUF60 protein purified from mammalian 293 cells for our
complementation; thus, it is possible that our PUF60 protein is
more active and/or our splicing substrates may be more efficient
or responsive to PUF60 activity.
PUF60 has other documented roles in the cell, and appears to
be a protein with particularly diverse functions. PUF60 is also
known as FBP-interacting repressor (FIR), a regulator of Myc gene
expression [37]. In this role, PUF60/FIR represses Myc
transcription in a process that involves binding between FIR and
FUSE-binding protein (FBP), which binds the Myc promoter
region. FIR/PUF60 itself was not found to bind the DNA, but
instead enhanced FBP binding. We did not detect an association
between FBP and PUF60 by western (data not shown) or by mass-
spectrometry of PUF60 immunoprecipitations. However, this
result does not preclude a relationship between these two proteins
under other conditions. A role for PUF60 in transcription as well
as splicing is intriguing, as this implies that PUF60 could
contribute to the coupling between these two processes (reviewed
in [38]).
Finally, PUF60 is also known as RoBPI (Ro RNA binding
protein) and interacts with Ro ribonucleoproteins (RNPs) [39]. Ro
RNPs have largely unknown functions, but are currently thought
to play a role in quality control of small RNAs (reviewed in [40]).
Cooperation between PUF60 and U2AF
65/35 has
a General Role in Splicing
The PyD splicing substrate with a weak pyrimidine tract was used
to initially identify PUF60 as a splicing factor. Previous analysis of
this substrate revealed that it requires both U2AF
65 and U2AF
35
for splicing, whereas splicing of the wild-type parental substrate is
not dependent on U2AF
35 ([41], Hastings&Krainer, unpublished
results). U2AF
35 recognizes the 39 splice-site AG dinucleotide and
stabilizes binding of U2AF
65 to the pyrimidine tract [5,7,8,9]. This
role for U2AF
35 may be particularly important in substrates with
weak pyrimidine tracts that are not bound efficiently by U2AF
65.
Similarly, PUF60 may be required in addition to U2AF
65 and
U2AF
35 to facilitate splice-site recognition. In these instances, in
which splicing is inefficient, the synergistic activity of these proteins
may be critical for splice-site identification.
We propose that 39 splice-site selection efficiency is dictated in
part by the ability of the site to be recognized by U2AF
65/35 and
PUF60. Splicing efficiency, as well as alternative splicing patterns,
could thereby be dictated by the availability, modifications, or
expression levels of these proteins. One possible function of the
proteins may be to displace inhibitory factors from the pyrimidine
tract. Indeed it has been reported that modulation of the levels of
U2AF
65 and the inhibitory protein PTB (polypyrimidine-tract-
binding protein) can influence alternative 39 splice-site selection
[42]).
Mechanistic Considerations for PUF60 in Splicing
Cooperation between PUF60 and U2AF
65/35 was observed for all
the splicing substrates tested, suggesting that this activity is an
integral part of the splicing process. Synergy between proteins in
splicing may reflect cooperative binding to a functional element(s),
or multiple, simultaneous interactions between the activators and
other components of the splicing machinery (reviewed in [43]).
Indeed, we find that having both PUF60 and U2AF
65/35 present
not only stimulates splicing in vitro in a cooperative manner, but
also influences their binding to the 39 splice-site region (Figures 4
and 5). Our gel shift experiments suggest that PUF60 and
U2AF
65/35 may bind sequentially, rather than simultaneously to
the RNA. One possible mechanism is that U2AF
65/35 binds
initially and recruits PUF60, which subsequently or concomitantly
displaces U2AF from the RNA. It is also possible that U2AF is not
fully displaced, but that its interaction with the 39 splice-site is
weakened in the presence of PUF60. This change in affinity could
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splicing proceeds. Although our analysis of the PUF60 complex
confirmed the presence of U2AF
65, only two peptides were found
by mass spectrometry (Table 1), suggesting that interactions
between the proteins may be relatively transient.
Spliceosome assembly in the 39 splice-site region of the intron is
very dynamic. Early in the process, interactions between SF1 and
the U2AF heterodimer allow for cooperative RNA binding that is
important for initial branchpoint sequence recognition [3]. An
interaction between SF3b155 and U2AF
65 replaces the U2AF
65-
SF1 interaction and is important for stable U2 snRNP binding to
the branchpoint sequence [44]. U2AF
65/35 binding to the RNA
also becomes destabilized during this process [45]. In our PUF60
complex (Table 1) we identified SF3b155 but not SF1. One
possible scenario is that SF1 binds cooperatively with U2AF
65,
which then recruits PUF60. The arrival of PUF60 could recruit
SF3b155 and initiate the replacement of U2AF-SF1 with
SF3b155, as well as the stable U2 snRNP association, accompa-
nied by destabilization of U2AF
65/35 binding. Many alternatives
can also be envisioned, including the possibility that PUF60
functionally overlaps with SF1 in the recruitment of U2AF
65 to the
RNA. Such a mechanism could explain why SF1 does not appear
to be essential for splicing in cells [46]. More detailed experiments
aimed at understanding the mechanistic interplay of PUF60 and
U2AF
65 are required to better define the interactions of these
proteins and the precise role of PUF60 in 39 splice site selection.
The isolated PUF60 complex (Figure 2 and Table 1) offers some
clues to the role of PUF60 in splicing. This complex is composed
mainly of splicing factors with functions in early spliceosome
assembly, including SR proteins and U1 and U2 snRNP
components, as well as a putative human homolog of PRP5, an
RNA-dependent ATPase. Interestingly, yeast PRP5 forms a bridge
between U1 and U2 snRNPs during pre-spliceosome assembly, an
association that appears to be important for U2 snRNP interaction
with the pre-mRNA [47]. The presence of these particular
components in the PUF60 complex further suggests that PUF60 is
involved in early spliceosome assembly, perhaps by helping to
recruit or stabilize U2 snRNP binding. Collectively, our results
suggest that PUF60 associates with a subset of splicing factors that
likely reflect its function in splicing during early events of the
reaction.
PUF60 and U2AF
65 as a Functional Class of Splicing
Factors
One model for the mechanism of PUF60 in splicing supported by
our results is that PUF60 and U2AF
65 have distinct functions in
splicing, but these functions may be partially interchangeable or
conditionally dispensable. Although it has been generally accepted
that U2AF
65 is required for pre-mRNA splicing in metazoans ([23]
and reviewed in [22]), we demonstrate that splicing in vitro can
occur in the absence of U2AF
65/35 (Figure 3). Under these
conditions, PUF60 is required in the extract to sustain splicing. At
the same time, these two proteins act cooperatively to stimulate
splicing at a level more than 5-fold greater than expected if the
activities of PUF60 and U2AF
65 were independent of each other.
Thus, although splicing can occur in the absence of either protein,
it is much more efficient when both are present.
Splicing was previously shown to occur in the absence of
U2AF
65 under certain experimental conditions. One report
provides evidence that when nuclear extract is prepared from
cells infected with adenovirus, in vitro splicing of some substrates is
dependent on the presence of U2AF
65 [48]; however, splicing of
other substrates can occur in the absence of U2AF
65. Another
study suggesting the dispensability of U2AF
65 reported that in vitro
splicing can be restored in U2AF-depleted extract by the addition
of an excess of the SR protein SC35 [49].
Our results raise the possibility that PUF60 and U2AF
65 may
belong to a family of factors that can modulate splicing based on
substrate-specific, early recognition of distinct 39 splice sites.
Another protein, HCC1, which is structurally related to PUF60
and U2AF
65 [50] may be another factor involved in this mode of
regulation. HCC1 has been shown to interact with splicing factors
such as SRp54 [51] and SRrp53 [52] and is found in the
spliceosome (reviewed in [15]). Related to the notion that these
proteins may represent a class of regulatory factors, a recent RNAi
screen in Drosophila aimed at identifying splicing regulators found
that knockout of hfp, the PUF60 ortholog, influences alternative
splicing of a partially overlapping set of substrates, compared to
knockout of HCC1 and U2AF50, the U2AF
65 ortholog [53].
Regulation of Alternative Splicing by PUF60 and
U2AF
65
If PUF60 and U2AF
65 can indeed modulate splicing based on
differential splice-site strengths and/or different requirements for
their activities in the splicing of particular introns, then regulation
of individual pathways via control of PUF60 and U2AF
65
expression levels, localization, or activities could play an important
role in alternative splicing and tissue-specific splicing. Indeed, we
have identified several alternative splicing events that are altered
by such fluctuations in cells (Figures 6 and 7).
Our observation that PUF60 depletion from HeLa cells shifts
APP and BIN1 processing to favor brain-specific splicing (Figure 6)
suggests that PUF60 may be one factor that helps determine non-
neuronal splicing patterns, and the relatively low levels of PUF60
in neuronal cell lines may be partially responsible for the observed
skipping of exon exons 7 and 8 in these cells. More extensive
experiments testing the effect of PUF60 over-expression in
neuronally-derived cells are required to confirm this activity. In
this first documented role of PUF60 in alternative splicing, the
protein appears to influence splicing of some regulated exons.
Interestingly, U2AF
65 had different effects on APP and BIN1
splicing compared to PUF60.
The regulation of splicing by PUF60 and U2AF
65 appears to be
complex, and at this point not readily predictable. We have
identified splicing events that are only altered by U2AF
65, others
that are altered in a similar fashion by both proteins, and still other
transcripts that are apparently unaffected by the depletion of either
protein. There are no obvious sequence patterns in the 39 splice
sites of these transcripts that correlate with PUF60 or U2AF
65
sensitivity. Identifying such features will be an important goal in
understanding the mechanism of regulation by these splicing
factors.
For some transcripts, such as BIN1 and SMN2, the depletion of
U2AF
65 (BIN1) or both U2AF
65 and PUF60 (SMN2) results in an
increase in exon inclusion. These results argue that as yet
unknown features of a splice site dictate its dependence on one
or the other protein. For example, in the case of SMN2, the
predominant skipping of exon 7 has been attributed to the
disruption of a splicing enhancer in exon 7 [54]. This splicing
enhancer is intact in the SMN1 gene—a paralog of SMN2—whose
transcripts efficiently include exon 7. Exonic splicing enhancers
recruit U2AF
65 to upstream 39 splice sites [55,56]. Thus, SMN2
exon 7 skipping may be a direct consequence of inefficient U2AF
65
binding. It is possible that the depletion of U2AF
65 weakens the
recognition of the exon 8 39 splice site, but has little effect on exon
7 splicing, which is already compromised in its ability to recruit
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65. Thus, the strength of the exon 7 and exon 8 39 splice sites
may be equalized by U2AF
65 or PUF60 depletion, and thus these
sites become more competitive for pairing with the 59 splice site of
exon 6. The outcome of this shift in splice-site recognition would
predict an increase in exon 7 inclusion, as observed in Figure 7.
Indeed, masking the exon 8 39 splice site with an antisense
oligonucleotide results in more efficient exon 7 inclusion [57].
Further evidence of a role of PUF60 in alternative splicing in vivo
comes from hypomorphic mutants of the Drosophila ortholog of
PUF60,Halfpint (Hfp),which exhibitalterationsindevelopmentally
regulated alternative splicing [58]. Knockout of Hfp [58] or the
PUF60 ortholog in C. elegans [59] is embryonic lethal, indicating an
essential role for the protein in invertebrate development.
Models for Splicing Regulation by PUF60 and
U2AF
65
The knockdown of PUF60 and U2AF
65 in cells results in changes
in certain alternative splicing patterns. In cells in which PUF60
and/or U2AF
65 levels become limiting, two possible scenarios can
be envisioned for the mechanism of splicing regulation. First, the
two proteins may substitute for each other in the splicing reaction,
similar to our observations in vitro. This could mean that one can
take over the function of the other, or that the activity of one can
compensate for loss of the activity of other. In either case,
recognition of individual splice sites may be affected differentially
by the loss of one or the other protein, depending on the relative
strength of a splice site’s interaction with, or dependence on,
PUF60 or U2AF
65. This model involving differential dependence
of individual 39 splice sites on PUF60 and U2AF
65 predicts an
alteration in splicing patterns when one of the proteins becomes
limiting. Alternatively, the lower levels of PUF60 and U2AF
65 may
result in a limited number of fully functional spliceosomes. Under
such limiting conditions, stronger splice sites are predicted to out-
compete weaker ones for binding by splicing factors, and thereby
alter splicing patterns. Differential recognition may be based on
the strength of interaction of the binding sites with splicing
components, or perhaps on the presence of specific sequences that
recruit PUF60 or U2AF
65 to the intron. Overall, our results
suggest that 39 splice-site strength may be defined in part by the
relative dependence on the cooperativity between PUF60 and
U2AF for recognition.
MATERIALS AND METHODS
Plasmids
To prepare pTT3-His PUFS and pTT3-HisPUFL, pGAD-GH-
RoBPI-47,3 and pGAD-GH-RoBPI-144,2 (kindly provided by G.
Boire, Universite ´ de Sherbrooke) were used as templates for PCR
with the primers PUF60Hisstart and PUFresmutD to generate
PUF60S and PUF60L (isoforms that lack or include alternative
exon 5, respectively). To prepare pTT3-HisU2AF35, PET19b-
U2AF35 (kindly provided by R.-M. Xu, New York University) was
used as a template for PCR with the primers U2AF35HISR and
U2AF35STOPL. Amplification products were digested with
HindIII and BamH I and ligated into pTT3 [60].
pGAD-GH-RoBPI-47,3 was used as a template for PCR with
the primers PUF60NdeR and PUF60BamL to generate a PUFS
fragment, which was digested with Nde I and BamH I and ligated
into pET9c vector (Novagen) to generate pET9c-PUF60S for
expression in E. coli.
pMARX-PUF60rm was made by overlap-extension PCR using
pGAD-GH-RoBPI-47,3 as a template and primers PUF60res-
mutA and PUF60resmutB and primers PUF60resmutC and
PUF60resmutD. PCR-amplified products obtained with primers
A and B were combined with product from reactions with primers
C and D and amplified with primers A and D. Resulting DNA was
digested with Hind III and BamH I and ligated into pTT3. This
template was used as a template in PCR with primers
BamPUFstartR and XhoPUFstop. The amplified product was
digested with BamH I and Xho I and ligated into pMarxIVpuro
(kindly provided by Greg Hannon, Cold Spring Harbor Lab).
To construct pBabe-F-V5-PUF60, the Bgl II restriction site in
PUF60L cDNA was mutated by overlap-extension PCR using
pTT3-HisPUFL as a template and the primers forwardA and
reverseA. The product was amplified by PCR using the primers
forwardB and reverseB and cloned in the BamH I and EcoRI
restriction sites of a modified pBluescript vector carrying at the N-
terminus the sequence coding for FLAG and V5 antigen (E. A.
and A.R.K., unpublished). The resulting vector was digested with
Bgl II-EcoR I and the F-V5-PUF60 fragment was subcloned into
BamHI - EcoR I-digested pBabe Puro vector.
The sequences of all primers used for PCR amplification are
shown in Table S1.
Templates for in vitro splicing were bWT and bPyD (kindly
provided by R.Reed, Harvard Medical School) linearized with
BamH I and transcribed with SP6 RNA polymerase; b-globin
linearized with BamH I and transcribed with SP6 polymerase
[61]; C12 (kindly provided by T. Nilsen, Case Western Reserve
University) linearized with Bgl II and transcribed with T3 RNA
polymerase; ftz (kindly provided by R. Reed, Harvard Medical
School) linearized with EcoRI and transcribed with T7 RNA
polymerase, and d-crystallin linearized with SmaI and transcribed
with Sp6 RNA polymerase.
RT-PCR
RNA was collected using Trizol Reagent (Invitrogen). Reverse
transcription was performed using a First-strand cDNA synthesis
kit (Amersham) with oligo dT primer. PCR with AmpliTaq Gold
(Roche) was carried out for 30 amplification cycles (95uC for 30 s,
58–60uC for 60 s, and 72uC for 60 s) in reactions containing
[a-
32P]dCTP. Primers for RT-PCR are provided in Table S1.
PCR analysis of SMN2 exon 7 splicing was performed as
previously described [54]. Products were separated on 6% native
polyacrylamide gels. Quantitation was based on phosphorimage
analysis (Fujix BAS2000 or Fujifilm FLA-5100).
Cell fractionation, in vitro transcription, and splicing
Frozen HeLa cells were prepared as described [17] and
resuspended in an equal volume of buffer A (10 mM Hepes-
KOH pH 8, 10 mM KCl, 1.5 mM MgCl2, 1mM DTT, 0.5mM
PMSF). Cells were lysed using a Dounce homogenizer. Nuclei
were recovered and resuspended in an equal volume of buffer C
(20 mM Hepes-KOH pH 8, 0.6 M KCl, 1.5 mM MgCl2,
0.2 mM EDTA, 25% (v/v) glycerol, 1 mM DTT, 0.5 mM PMSF)
and lysed in a Dounce homogenizer, followed by rocking for
30 min at 4uC. The supernatant following centrifugation was
dialyzed against buffer D (20 mM Hepes, 100 mM KCl, 0.2 mM
EDTA, 0.5 mM PMSF, 1mM DTT, 20% (v/v) glycerol). This
nuclear extract was diluted 3-fold with buffer E (20 mM Hepes-
KOH pH 8, 0.2 mM EDTA, 1 mM DTT) and mixed with buffer
E-AS (saturated with ammonium sulfate) to obtain a final
concentration of 20%-saturated ammonium sulfate. The mixture
was rotated for 60 min at 4uC and centrifuged. Dry ammonium
sulfate (0.11 g/ml) was added to the supernatant and dissolved by
rotation at 4uC for 45 min and centrifuged. The pellet was
resuspended in buffer D and dialyzed into buffer D to yield the
20–40% AS fraction.
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CsCl (1 g/ml) to the 20–40% AS fraction and handled as
described [62]. Gradient fractions were dialyzed into buffer D.
Active fractions were pooled and loaded onto a 1610 cm Poros 20
Heparin column on an AKTA Purifier (Amersham Pharmacia).
Bound proteins were eluted by stepwise washes of buffer D-1M
NaCl, and buffer D-2M NaCl. The 2M eluate was dialyzed
against buffer D, denatured by the addition of solid urea to a final
concentration of 6M and loaded onto a 165 cm Poros 20 HQ
column equilibrated in buffer D-6M urea. Proteins were eluted
with a linear gradient from buffer D-0.1 M to -2 M NaCl with 6M
urea. Fractions were dialyzed against buffer D-0.1 M KCl.
Fraction 18 from the Poros HQ column was digested with
trypsin and peptides were analysed by liquid chromatography-
MS/MS using 75-mm615-cm C18 picofrit columns (New
Objectives) coupled to an LTQ mass spectrometer and peptides
were eluted using a 10–85% MeOH gradient in 0.5% acetic acid.
Peptide fragmentation spectra were extracted using the READW
program and searched using X!Tandem.
In vitro transcription and splicing reactions were carried out as
described [63]. Nuclear extract were prepared as described [64].
PUF60 and U2AF
65/35 were depleted from HeLa nuclear extract
by poly(U)-Sepharose chromatography as previously described [5].
Products were separated on denaturing polyacrylamide gels.
Quantitation was based on phosphorimage analysis (Fujix
BAS2000 or Fujifilm FLA-5100).
Western blot analysis
Western blotting was performed using rabbit polyclonal antibodies
specific for PUF60 (kindly provided by G. Boire, Universite ´d e
Sherbrooke), or U2AF
35 (kindly provided by B. Graveley, University
of Connecticut Health Center), and SRrp86 (kindly provided by J.
Patton, Vanderbilt University), and mouse monoclonal antibodies
specific for human U2-B’’ snRNP protein (mAb 4G3), PUF60
(M.L.H. and A.R.K. unpublished data), U2AF
65 (A.R.K., un-
published),SRp55(L.Mancheand A.R.K.,unpublished data),SF2/
ASF (mAb96), hnRNP A1 (mAb A1/55, L. Manche and A.R.K.,
unpublished), V5 (Invitrogen), and a-tubulin (Sigma). Quantitation
was performed using Alexafluor 532 anti-mouse or Alexafluor 488
anti-rabbit secondary antibodies (Molecular Probes) followed by
analysis on a Fujifilm Fluor Imager FLA-5100.
Tissue culture and transfection
PUF60rm cell lines were generated by retroviral transduction with
pMarx-PUF60rm or vector alone as described [65]. The HeLa S3
cell line expressing F-V5-PUF60L was generated by viral infection
with pBabe-F-V5-PUF60L as described [66]. A clonal HeLa S3
cell line stably expressing the tagged protein at a high level was
selected by immunofluorescence using the anti-V5 antibody
(Invitrogen) and expanded to prepare nuclear extract [64].
RNA interference
10
5 untransfected HeLa cells or HeLa cells expressing either pMarx
or pMarx-PUF60rm were seeded into 6-well plates 24 h before
transfectionofsiRNAwithOligofectamine(Invitrogen).ThesiRNAs
used were: PUF60 r(GCAGAUGAACUCGGUGAUG)dTdT
(sense strand, Dharmacon) and U2AF
65 (U2AF2: r(GCAA-
GUACGGGCUUGUCAA)dTdT (sense strand, Qiagen). After
72 h cells were harvested for RNA isolation and western blotting.
Recombinant proteins
E. coli-derived recombinant PUF60 was prepared from BL21 cells
expressing pET9c-PUF60S. Cell pellets were sonicated in buffer D
and, following centrifugation, MgCl2 (15 mM final concentration)
was added to the supernatant. Proteins were precipitated on ice for
10 min and centrifuged. The pellet was resuspended in buffer D,
sonicated, and treated to another round of precipitation as above.
The final pellet was resuspended in buffer D and loaded on
a heparin column with 100 mM NaCl. PUF60 was present in the
flow-through, which was dialyzed overnight in buffer D with 5%
(v/v) glycerol.
Mammalian-cell-derived PUF60 and U2AF
65/35 were expressed
in 293E cells transiently transfected with pTT3-HisPUFS or
pTT3-HisU2AF35 in a procedure adapted from a published
method [60]. For purification, cell pellets were resuspended in lysis
buffer (50 mM Tris-HCl, pH 8, 1% NP-40, 5 mM imidazole,
5 mM NaF, 5 mM b-glycerophosphate, 1 mM DTT), sonicated
and centrifuged. Supernatant was added to a 0.5 ml Ni-NTA
agarose (Qiagen), and rotated at 4uC for 1 h. The slurry was
packed on a column and the beads were washed with 50 mM Tris,
0.5 M NaCl, 5 mM imidazole. Bound protein was eluted with
50 mM Tris, 500 mM NaCl, 0.5 M imidazole, and dialyzed into
buffer D. Protein concentrations were estimated by comparing
protein preparations to serial dilutions of a bovine serum albumin
(BSA) standard in SDS-PAGE gels stained with Coomassie
Brilliant Blue R (Sigma). The purified U2AF heterodimer has
a U2AF
35 to U2AF
65 stoichiometry of ,3.5:1.
Baculovirus-derived recombinant human SC35 and U2AF
65/35
were purified from infected SF9 cells as described previously
([56,63], respectively). The purified U2AF heterodimer has
a U2AF
35 to U2AF
65 stoichiometry of ,1:1
Immunoprecipitation
Nuclear extract prepared from the HeLa S3 cell line expressing F-
V5-PUF60L or from standard HeLa S3 cells were dialyzed into IP
buffer (20 mM Hepes, pH 8, 150 mM KCl, 1.5 mM MgCl2,
0.5 mM PMSF, 5% (v/v) glycerol), centrifuged to remove
insoluble material, and incubated with rotation for 1 h at 4uC
with ANTI-FLAG M2 Affinity Gel (Sigma) which had been
washed three times with IP buffer containing 0.05% (v/v) Triton
X-100. 1 ml of nuclear extract was added to 20 ml of beads.
Following incubation, the beads were washed once with IP buffer
except with 250 mM KCl, 0.05% (v/v) Triton X-100 and 200 ng/
ml of RNase A, twice with the same buffer without RNase A, and
twice with IP buffer with 100 mM KCl. Beads with bound protein
were either directly digested with trypsin and analyzed by LCQ
MS/MS or were eluted in IP buffer with 100 mM KCl and
100 ng/ml Flag peptide (Sigma). Eluted proteins were separated
on an SDS-PAGE gradient gel, and major peptides were excised,
digested with trypsin, and identified by LC-MS/MS as above.
Gel-shift assay
Proteins were incubated with radiolabeled RNA (,0.2 nM final
concentration) in binding buffer [25 mM Tris (pH 7.5), 25 mM
NaCl, 1 mM EDTA] with 0.1 mg/ml tRNA and 0.5 mg/ml BSA
for 60 min at room temperature. RNA and RNA-protein
complexes were separated in 0.5 TBE 6% native polyacrylamide
gels run at 100V in the cold room. Binding was quantitated by
calculating the fraction of bound RNA (specific protein-RNA
complex) relative to all other unbound or bound RNA.
Footprint analysis
Reactions were assembled identical to those in gel-shift assays,
except that RNasin (Promega) was included at a final concentra-
tion of 1 U/ml. After a 30-min incubation, tRNA (2.6 mg/ml
final concentration) and either RNase T1 (Ambion, final
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tration of 0.6 U/ml) was added to the reaction and incubated for
5 min at room temperature followed by phenol extraction and
ethanol precipitation. Products were separated on a 20% de-
naturing polyacrylamide gel.
SUPPORTING INFORMATION
Figure S1 Figure S1. Analysis of U2AF
65 for RESCUE activity.
(A) Recombinant U2AF
65/35 complements splicing in depleted
extracts. In vitro splicing assay using the b-globin WT construct in
reactions containing nuclear extract (NE) or extract depleted of
U2AF
65/35 (DNE, lane 2), or depleted extracts with recombinant
U2AF
65/35 (lane 3) from baculovirus or U2AF
65 from E. coli (lane
4). (B) In vitro splicing assay using the PyDsubstrate in reactions
containing nuclear extract (lane 1) S100 extract alone (lane 2) or
with SR proteins (lane 3) or S100 extract with SR proteins and
recombinant baculovirus U2AF
65/35 (lanes 4–5), or U2AF
65
purified from E. coli (lane 6). Unspliced pre-mRNA and spliced
mRNA are indicated.
Found at: doi:10.1371/journal.pone.0000538.s001 (0.83 MB TIF)
Figure S2 Figure S2. Purification of RESCUE activity by HQ
chromatography. (A) Column profile. Fractions with RESCUE
activityfromthe Poros20heparinchromatographystepwere loaded
ontoa Poros 20HQcolumninlow saltunder denaturing conditions,
and the proteins were eluted by a salt gradient. The A280 (blue),
A260 (red), and conductivity (brown) and gradient (green) tracings
are shown. The peak splicing activity as detected by in vitro splicing
is indicated. (B) In vitro splicing of PyD pre-mRNA. Fractions from
the gradient and flow-through were assayed in reactions containing
nuclear extract (NE), S100 extract (S), or S100 extract and SC35
without (-) or with gradient fractions. H refers to the active fraction
from the heparin column. H* refers to the active heparin fraction
after denaturation and renaturation with urea, analogous to the
treatment of the HQ fractions.
Found at: doi:10.1371/journal.pone.0000538.s002 (6.80 MB TIF)
Figure S3 Figure S3. Analysis of PUF60 and U2AF
65/35
depletion from HeLa nuclear extract. (A) Scheme for the
fractionation of nuclear extract using poly(U)-Sepharose resin.
(B) Western blot analysis of fractions. D refers to the depleted
nuclear extract (column flow-through), W refers to the 2M NaCl
wash, E represents the 2M guanidinium-HCl eluate, and PUF
refers to recombinant PUF60 (lane 5, ,6 pmol). (C) Analysis of
extract depletion and relative levels of recombinant PUF60 and
(D) U2AF
65/35 used for complementation in Fig. 3. Western blot
analysis of serial dilution of nuclear extract (lanes 1–6) compared
to depleted extract (D, lane 7). The PUF60 blot shows His-tagged
PUF60 (,3.6 pmol) purified from HEK-293E cells (lane 8).
Approximately 60% of the protein forms an SDS-resistant dimer
(*). The monomer corresponds to about 1.4 pmol/ml. Quantitation
of the signals indicates that 3.4 pmol of PUF60 corresponds to
,80% of the PUF60 in nuclear extract. The U2AF
65/35 purified
protein preparation from HEK-293E cells expressing His-tagged
U2AF
35 was analyzed by western (,4.2 pmol U2AF
35 and ,1.2
pmol U2AF
65, as estimated by comparison to bovine serum
albumin standard) and compared to the standard curve for nuclear
extract (lanes 1–6). The purified U2AF
65 and U2AF
35 from HEK-
293E cells correspond to approximately 9 and 17% of the
concentration of U2AF
65 and U2AF
35 in nuclear extract,
respectively. Blots were probed with antibodies specific to the
indicated protein. (E) Complementation of in vitro splicing of PyD
pre-mRNA in nuclear extract depleted of PUF60 and U2AF
subunits. PyD pre-mRNA spliced in nuclear extract (NE, lane 1),
depleted extract with the PUF60-containing 2M NaCl wash only
(lane 2), or complemented also with human recombinant U2AF
65/
35 purified from baculovirus-infected SF9 cells.
Found at: doi:10.1371/journal.pone.0000538.s003 (1.32 MB TIF)
Figure S4 Figure S4. Cooperative activity of PUF60 and
U2AF
65/35 in ftz splicing in vitro. (A) ftz pre-mRNA spliced in
nuclear extract (NE, lane 1), extract depleted of U2AF subunits
and PUF60 (DNE, lane 2), depleted extract complemented with
recombinant HEK-293E-expressed PUF60 alone (lanes 3–5: 1.2,
2.4, 4.8 mM final concentration, respectively), or PUF60 (1.2
{lower case}M final concentration) with recombinant U2AF
65/35
purified from HEK-293E cells (lane 6–8: 33, 67, 133 nM final
concentration of U2AF
65, respectively), or with U2AF
65/35 alone
(lanes 9–11: 67, 133, 200 nM of of U2AF
65). (B) Quantitation of
ftz splicing with the three concentrations of proteins shown in (A).
The level of splicing expected if the PUF60 and U2AF activity is
additive was calculated as the sum of lanes 3+9, 4+10, and 5+11,
respectively (Sum).
Found at: doi:10.1371/journal.pone.0000538.s004 (0.82 MB TIF)
Figure S5 Figure S5. Recombinant PUF60 and U2AF
65/35.
Coomassie-blue-stained SDS gel of recombinant PUF60 purified
from HEK-293E cells (,0.2 mg, lane 1), and recombinant
U2AF
65/35 heterodimer purified from baculovirus-infected SF9
cells (lane 2; 0.25 and 0.12 mg, respectively). Bovine serum
albumin (BSA) was included to confirm the protein concentration
(lanes 3–6; 0.05, 0.1, 0.2 and 0.4 mg, respectively).
Found at: doi:10.1371/journal.pone.0000538.s005 (0.21 MB TIF)
Figure S6 Figure S6. Shift-western blot analysis. (A) Gel-shift
analysis of the
32 P-labeled AdML 39 splice-site fragment
incubated alone (-, lane 1) or in the presence of PUF60 (lanes 2–
7, 10–13) and/or U2AF
65 (lanes 5–12). Reactions were separated
on a 6% native polyacrylamide gel and electrophoretically
transferred to sandwiched nitrocellulose and nylon membranes.
The nitrocellulose membrane binds the protein and the RNA is
transferred to the nylon membrane which is shown. (B) Western
blot analysis of nitrocellulose membranes prepared as described
above using an antibody against U2AF
65. (C) Gel-shift analysis of
the
32 P-labeled AdML 39 splice-site fragment incubated alone (-,
lane 1) or in the presence of PUF60 (lanes 2–7, 12–15) and/or
U2AF
65 (lanes 5–15). Reactions were treated as described above
and nylon membrane with immobilized RNA is shown. (D)
Western blot analysis of the gel in (C) using a PUF60-specific
antibody.
Found at: doi:10.1371/journal.pone.0000538.s006 (5.60 MB TIF)
Figure S7 Figure S7. Cell-type-specific APP and BIN1 splicing
and PUF60 and U2AF
65 expression. (A) Western blot analysis of
whole-cell extracts (,2.5, 5, and 106104 cell equivalents, lanes 1–
3 and 4–6, respectively) from WERI (lane 1–3) and HeLa cells
(lane 4–6) separated by 12% SDS-PAGE. Blots were probed with
antibodies specific to PUF60 and a-tubulin (top) or to U2AF
65 and
a-tubulin (middle). (B) Quantitation of PUF60 and U2AF
65
protein levels. Blots were probed with a fluorescent secondary
antibody and fluorescence was quantitated on a Fujifilm FLA-
5100. The measurements showed a direct linear relationship
between increasing amounts of input sample and fluorescence.
Error bars represent the S.E.M of the three measurements from
the blot shown in A.
Found at: doi:10.1371/journal.pone.0000538.s007 (0.40 MB TIF)
Table S1 Table S1: Sequences of primers used in PCR
reactions.
Found at: doi:10.1371/journal.pone.0000538.s008 (0.05 MB
DOC)
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